Enclomiphene vs Gonadorelin
Two ways to raise a man's own testosterone while preserving fertility — one restarts the brain's pulsatile signal directly, the other blocks estrogen's feedback on that same signal.
Short answer
The clearest difference is regulatory. Gonadorelin is FDA-approved, and enclomiphene is not FDA-approved. Gonadorelin suits a reader who puts weight on FDA approval, though that approval does not cover every use it is marketed for, while enclomiphene is marketed for raising testosterone and preserving fertility. On the evidence, enclomiphene has human clinical data and gonadorelin has approval-level evidence.
Enclomiphene
Randomized Phase III data: restores a man's own testosterone while preserving sperm — but never FDA-approved for men, and compounded.
Full Enclomiphene evidence reviewGonadorelin
GnRH
Authentic synthetic GnRH with legitimate diagnostic and pulsatile-pump fertility roles — but the modern once-daily bolus use as an hCG substitute on TRT ignores the rhythm the evidence depends on.
Full Gonadorelin evidence reviewEnclomiphene vs Gonadorelin: head to head
- FDA status / approved use
Enclomiphene
Not FDA-approved; its application for male hypogonadism was not approved, so use is off-labelGonadorelin
Approved in the US as a one-time diagnostic test (Factrel); not approved for TRT use- Marketed for
Enclomiphene
Raising testosterone, preserving fertilityGonadorelin
Fertility, TRT adjunct (hCG substitute)- Outcome areas
Enclomiphene
Testosterone / male hormonesGonadorelin
Female hormones / fertility / PCOS; Testosterone / male hormones- Evidence grade
Enclomiphene
Clinical dataGonadorelin
FDA-approved- How it works
Enclomiphene
Blocks estrogen feedback so LH, FSH and the body's own testosterone riseGonadorelin
Synthetic GnRH that signals the pituitary to release LH and FSH- Route and dosing
Enclomiphene
Oral medicationGonadorelin
Injection once or twice daily in clinics; pump pulses for fertility- Headline human result
Enclomiphene
Testosterone up +7.50 nmol/L in a 2023 meta-analysis of 7 studies (292 men); clomiphene raised it moreGonadorelin
Pump therapy brought first sperm at a median 6 vs 18 months on hCG plus hMG in 202 men (2017)- Strongest evidence
Enclomiphene
Phase III RCT, BJU Int 2016Enclomiphene evidence reviewPubMed 26496621Gonadorelin
Hoffman, NEJM 1982Gonadorelin evidence reviewPubMed 6813732- Key safety signal
Enclomiphene
No long-term data on bone, heart or mortality outcomesGonadorelin
Continuous or poorly timed dosing desensitizes the pituitary and can shut the axis down- How it is obtained
Enclomiphene
Prescribed off-label and dispensed by compounding pharmaciesGonadorelin
Prescribed and dispensed by compounding pharmacies; legality varies by compound
| Enclomiphene | Gonadorelin | |
|---|---|---|
| FDA status / approved use | Not FDA-approved; its application for male hypogonadism was not approved, so use is off-label | Approved in the US as a one-time diagnostic test (Factrel); not approved for TRT use |
| Marketed for | Raising testosterone, preserving fertility | Fertility, TRT adjunct (hCG substitute) |
| Outcome areas | Testosterone / male hormones | Female hormones / fertility / PCOS; Testosterone / male hormones |
| Evidence grade | Clinical data | FDA-approved |
| How it works | Blocks estrogen feedback so LH, FSH and the body's own testosterone rise | Synthetic GnRH that signals the pituitary to release LH and FSH |
| Route and dosing | Oral medication | Injection once or twice daily in clinics; pump pulses for fertility |
| Headline human result | Testosterone up +7.50 nmol/L in a 2023 meta-analysis of 7 studies (292 men); clomiphene raised it more | Pump therapy brought first sperm at a median 6 vs 18 months on hCG plus hMG in 202 men (2017) |
| Strongest evidence | Phase III RCT, BJU Int 2016Enclomiphene evidence reviewPubMed 26496621 | Hoffman, NEJM 1982Gonadorelin evidence reviewPubMed 6813732 |
| Key safety signal | No long-term data on bone, heart or mortality outcomes | Continuous or poorly timed dosing desensitizes the pituitary and can shut the axis down |
| How it is obtained | Prescribed off-label and dispensed by compounding pharmacies | Prescribed and dispensed by compounding pharmacies; legality varies by compound |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- FDA-approved:
- Approved by the FDA for a defined indication, on the strength of pivotal human trials.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Enclomiphene has real Phase 3 data for exactly this use: raising testosterone while preserving sperm production, though it's never been FDA-approved for men and is compounded. Gonadorelin is authentic synthetic GnRH with legitimate pulsatile-pump fertility applications, but the popular once-daily bolus injection used as a TRT-adjunct ignores the pulsatile rhythm the actual evidence depends on — a real mismatch between how it's studied and how it's sold.
Enclomiphene fits if
You want the option with actual Phase 3 trial data behind its off-label use as a standalone fertility-preserving testosterone raiser.
Gonadorelin fits if
You're specifically working within a legitimate pulsatile-pump protocol with a fertility specialist, not using it as a once-daily TRT adjunct.
Enclomiphene vs Gonadorelin: common questions
- Is gonadorelin FDA-approved but enclomiphene not?
- Yes. Gonadorelin is approved in the US as a one-time diagnostic test (Factrel); not approved for TRT use. Enclomiphene is not FDA-approved; its application for male hypogonadism was not approved, so use is off-label.
- Which has stronger human evidence, enclomiphene or gonadorelin?
- Gonadorelin. It has approval-level evidence (key source: Hoffman, NEJM 1982), while enclomiphene has human clinical data (key source: Phase III RCT, BJU Int 2016).
- What are the main safety concerns with enclomiphene and gonadorelin?
- Enclomiphene has no long-term data on bone, heart or mortality outcomes. With gonadorelin, continuous or poorly timed dosing desensitizes the pituitary and can shut the axis down.
Key studies behind each
Enclomiphene
- Kaminetsky J, Werner M, Fontenot G, Wiehle RD. (2013). Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med. PubMed 23530575
- Wiehle R, Cunningham GR, Pitteloud N, et al. (2013). Testosterone restoration by enclomiphene citrate in men with secondary hypogonadism: pharmacodynamics and pharmacokinetics. BJU Int. PubMed 23875626
- Wiehle RD, Fontenot GK, Wike J, et al. (2014). Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. PubMed 25044085
- Kim ED, McCullough A, Kaminetsky J. (2016). Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. PubMed 26496621
Gonadorelin
- Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. (1978). Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science. PubMed 100883
- Hoffman AR, Crowley WF Jr. (1982). Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med. PubMed 6813732
- Mao JF, Liu ZX, Nie M, et al. (2017). Pulsatile gonadotropin-releasing hormone therapy is associated with earlier spermatogenesis compared to combined gonadotropin therapy in patients with congenital hypogonadotropic hypogonadism. Asian J Androl. PubMed 28051040
- Boehm U, Bouloux PM, Dattani MT, et al. (2015). Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism — pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. PubMed 26194704
The full evidence reviews
- Enclomiphene: the evidence for restoring testosterone without replacing it
Randomized trials, including two Phase III RCTs, show enclomiphene restores a man's own testosterone while preserving fertility — but it was never FDA-approved.
Updated August 2026
- Gonadorelin: real GnRH with a proven pump role, and an unproven TRT-adjunct pitch
Gonadorelin is authentic synthetic GnRH with a legitimate diagnostic and pulsatile-pump fertility role, but the modern once-daily bolus use as an hCG substitute on TRT ignores the rhythm the evidence depends on.
Updated October 2026
Where to get it
Where to get testosterone therapy
Testosterone and hormone-optimization telehealth services with clinician oversight and lab work. Confirm current pricing and lab requirements — and whether Enclomiphene fits your case — with the provider.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
Peter MDPartnerTRT from a one-stop men's-health provider, with enclomiphene and GLP-1 too
MangoRxPartnerAdults considering compounded injection TRT who will confirm the complete monitoring quote
DudeMedsPartnerMen who specifically want branded rather than compounded testosterone and can prepay a term
Provider reviews we publish: WellMedRxFountain TRTElitePhysiqMDEvolve TelemedFeel30Fresh Day Meds